Incidence of and Risk Factors for Patients in Intensive Care Units to Acquire Infection or Colonization of Community-associated Methicillin-resistant Staphylococcus aureus
Wang JT et al. – The incidence of and risk factors for acquiring community–associated methicillin–resistant Staphylococcus aureus among patients staying in intensive care units remain unclear. The authors enrolled patients staying in two intensive care units at the Far Eastern Memorial Hospital during the period of September 1, 2008 to September 30, 2009 to clarify this issue. Surveillance cultures for methicillin–resistant Staphylococcus aureus were taken from nostril, sputum or throat, axillae, and the inguinal area in all enrolled patients upon admission to the intensive care units, then every three days, and on the day of discharge from the intensive care units. read more
Empiric Outpatient Therapy with Trimethoprim-Sulfamethoxazole, Cephalexin, or Clindamycin for Cellulitis
Khawcharoenporn T et al. – Antibiotics with activity against community–associated methicillin–resistant Staphylococcus aureus, such as trimethoprim–sulfamethoxazole and clindamycin, are preferred empiric therapy for outpatients with cellulitis in the community–associated methicillin–resistant Staphylococcus aureus–prevalent setting.
read more
Health care-associated and community-associated methicillin-resistant Staphylococcus aureus infections: A comparison of definitions
McCarthy NL et al. – The authors found few differences between CA– and HA–MRSA infections, regardless of how health care–association was defined. They believe that the migration of CA–MRSA into health care settings and the recent increasing antibiotic resistance of CA–MRSA strains contribute to the lack of factors associated with HA (vs CA) MRSA.
read more
Risk factors associated with long-term prognosis of patients with Staphylococcus aureus bacteremia
Hanses F et al. – To estimate risk factors associated with long–term outcome (i.e., 1–year survival) in patients with Staphylococcus aureus bacteremia. In summary, in this patient cohort, considerable additional mortality due to staphylococcus aureus bacteremia beyond 30 or 90 days was present. The authors results suggest that long–term survival data should be taken into account in outcome studies involving patients with Staphylococcus aureus bacteremia.
read more
Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
Barbour A et al. – Ceftobiprole has demonstrated noninferiority in two large–scale pivotal studies comparing it to vancomycin, clinical cure rates 93.3% vs 93.5%, respectively, or vancomycin plus ceftazidime, clinical cure rates 90.5% vs 90.2%, respectively. Given the pharmacokinetic and pharmacodynamic properties, ceftobiprole is a promising new agent for the treatment of cSSSIs and has the potential to be used as a single agent for empiric treatment. read more
